Extended Anticoagulation with Reduced-Dose Non-inferior to Full-Dose Apixaban for the Prevention of Recurrent VTE in Patients with Active Cancer By Ogkologos - April 29, 2025 670 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the API-CAT study Source RELATED ARTICLESMORE FROM AUTHOR In Memory of Hernán Cortés-Funes: Former ESMO President and Pioneer in Medical Oncology Immune Pathways Help Identify Patients with Cancer and HIV Most Likely to Experience Reservoir Decay with Anti-PD1 Therapy Shaping Future Oncology Leaders: ESMO Broadens Its Career Development Opportunities MOST POPULAR How a Musician Copes With Life With Metastatic Breast Cancer March 17, 2021 Pembrolizumab Improves Survival in Advanced Triple-Negative Breast Cancer August 9, 2022 Into the archives: the story of HPV and cervical cancer November 21, 2022 Mental Health Awareness for Health Care Providers May 21, 2021 Load more HOT NEWS Chris Pratt Partners with GreaterGood to Support Food Banks and Feed... Forging Military Partnerships to Empower the Cancer Research Enterprise Breast Cancer Survivor is Swimming the English Channel to Benefit Mental... Shaping Cancer Care in Asia: ESMO Brings Research and Patient Voices...
